JP2018186833A5 - - Google Patents

Download PDF

Info

Publication number
JP2018186833A5
JP2018186833A5 JP2018149864A JP2018149864A JP2018186833A5 JP 2018186833 A5 JP2018186833 A5 JP 2018186833A5 JP 2018149864 A JP2018149864 A JP 2018149864A JP 2018149864 A JP2018149864 A JP 2018149864A JP 2018186833 A5 JP2018186833 A5 JP 2018186833A5
Authority
JP
Japan
Prior art keywords
seq
protein consisting
composition
amount
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018149864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018186833A (ja
Filing date
Publication date
Priority claimed from US13/663,527 external-priority patent/US10028998B2/en
Application filed filed Critical
Publication of JP2018186833A publication Critical patent/JP2018186833A/ja
Publication of JP2018186833A5 publication Critical patent/JP2018186833A5/ja
Pending legal-status Critical Current

Links

JP2018149864A 2012-10-30 2018-08-09 Fcγ受容体IIB変異体 Pending JP2018186833A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/663,527 2012-10-30
US13/663,527 US10028998B2 (en) 2012-10-30 2012-10-30 Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015538506A Division JP6423351B2 (ja) 2012-10-30 2013-10-30 Fcγ受容体IIB変異体

Publications (2)

Publication Number Publication Date
JP2018186833A JP2018186833A (ja) 2018-11-29
JP2018186833A5 true JP2018186833A5 (https=) 2019-01-17

Family

ID=49679480

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015538506A Active JP6423351B2 (ja) 2012-10-30 2013-10-30 Fcγ受容体IIB変異体
JP2018149864A Pending JP2018186833A (ja) 2012-10-30 2018-08-09 Fcγ受容体IIB変異体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015538506A Active JP6423351B2 (ja) 2012-10-30 2013-10-30 Fcγ受容体IIB変異体

Country Status (27)

Country Link
US (1) US10028998B2 (https=)
EP (1) EP2914624B1 (https=)
JP (2) JP6423351B2 (https=)
KR (1) KR102170674B1 (https=)
CN (1) CN104918955B (https=)
AU (1) AU2013340831B2 (https=)
BR (1) BR112015008815A2 (https=)
CA (1) CA2887164C (https=)
CL (1) CL2015001127A1 (https=)
DK (1) DK2914624T3 (https=)
EA (1) EA033437B9 (https=)
ES (1) ES2628049T3 (https=)
HR (1) HRP20170894T1 (https=)
HU (1) HUE032786T2 (https=)
IL (1) IL238528A (https=)
IN (1) IN2015DN03206A (https=)
LT (1) LT2914624T (https=)
MX (1) MX359802B (https=)
MY (1) MY173686A (https=)
NZ (1) NZ706884A (https=)
PH (1) PH12015500771B1 (https=)
PL (1) PL2914624T3 (https=)
PT (1) PT2914624T (https=)
RS (1) RS56075B1 (https=)
SG (1) SG11201502749VA (https=)
SI (1) SI2914624T1 (https=)
WO (1) WO2014068012A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
EP2796144A1 (en) * 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
NZ719745A (en) * 2013-10-16 2018-10-26 Suppremol Gmbh Soluble fc gamma receptor for treatment of autoimmune bullous diseases
JP6710451B2 (ja) * 2016-03-31 2020-06-17 東ソー株式会社 改変型組換えFcγRIIb
WO2020002252A1 (de) * 2018-06-25 2020-01-02 Basf Coatings Gmbh Verfahren zur herstellung einer optimierten beschichtung und mittels dieses verfahrens erhältliche beschichtung
CN111454914A (zh) * 2019-01-18 2020-07-28 嘉兴安宇生物科技有限公司 一种腺病毒快速纯化方法
KR20250122541A (ko) 2022-10-25 2025-08-13 사이즈믹 테라퓨틱, 인코포레이티드. 변이체 IgG FC 폴리펩티드 및 그 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DE10157290A1 (de) 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
NZ547629A (en) 2003-11-26 2009-08-28 Max Planck Gesellschaft Antibodies binding to conformationally discriminating epitopes of human IGG Fc receptor IIb and IIb
EP1960427B1 (en) 2005-12-13 2011-02-23 SuppreMol GmbH Multimeric fc receptor polypeptides
EP1870442A1 (en) * 2006-06-19 2007-12-26 DSMIP Assets B.V. Air drying resin and composition
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
EP2623112B1 (en) 2008-06-27 2015-03-04 Zymogenetics, Inc. Soluble hybrid Fc gamma receptors and related methods
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb

Similar Documents

Publication Publication Date Title
JP2018186833A5 (https=)
JP2018100276A5 (https=)
JP2018012698A5 (https=)
IL276830A (en) Anti-claudin 18.2 antibodies and uses thereof
JP2019142968A5 (https=)
EP3878863A4 (en) ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE
ZA202103061B (en) Anti-cldn18.2 antibody and uses thereof
ZA202106880B (en) Anti-claudin 18.2 antibody and application thereof
CN109843893A (zh) 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
JP2017048194A5 (https=)
JP2018064407A5 (https=)
JP2017501211A5 (https=)
JP2020532288A5 (https=)
MX2023014145A (es) Oligonucleotidos modificados y metodos de uso.
JP2018127649A5 (https=)
LT3979827T (lt) Maistinė kompozicija, apimanti 2‘-fukozillaktozę ir 3‘-galaktozillaktozę
WO2020235974A3 (ko) 단일염기 치환 단백질 및 이를 포함하는 조성물
JP2021129286A5 (https=)
EP3789382A4 (en) PROCESS FOR THE PRODUCTION OF 4,5-DIHYDROISOXAZOLE 5,5-DISUBSTITUTED
JP2022536655A5 (https=)
CN110809579A (zh) 多肽的药学可接受的盐及其应用
JP2020531778A5 (https=)
JP2019512693A5 (https=)
JP2019218304A5 (https=)
JP2022506891A5 (https=)